Dr. Camron Bryant to chair 2014 IBANGS symposium

January 13th, 2014 in Recent News

2012-11-08 13.09.15 BRYANT, Cameron_2Dr. Camron Bryant’s symposium proposal for the 2014 Annual Genes, Brain and Behavior Meeting of the International Behavioural and Neural Genetics Society Meeting has been accepted as one of six symposia scheduled for this year’s meeting. The 16th annual conference will be held in Chicago, IL from May 10-13.

The title of the symposium that Dr. Bryant will chair is, “Behavioral, neural and genetic studies of compulsive eating in model organisms and humans.” The objective of this symposium is to highlight recent behavioral, neural, and genetic studies of compulsive eating that lie within the framework of addiction and to inform future studies in model organisms and humans.

Dr. Bryant, Assistant Professor of Pharmacology and Psychiatry, is the Director of the Laboratory of Addiction Genetics at Boston University School of Medicine.

Congratulations, Dr. Bryant!

BUSM Researcher Receives Grant from CURE

January 6th, 2014 in Recent News

ShelleyShelley J. Russek, PhD, professor of pharmacology at Boston University School of Medicine (BUSM), and director of the School’s Graduate Program for Neuroscience, was recently honored with an award from the CURE (Citizens United for Research in Epilepsy) Foundation. The prestigious award, given as well to her colleague Amy Brooks-Kayal, MD, from University of Colorado Denver, will fund research studies for new drugs for epilepsy treatment.

Approximately 65 million people worldwide have epilepsy. Although certain brain injuries are known to predispose someone to epilepsy, there are no treatments that reduce this risk. Russek and her colleagues have found that an important cellular signaling pathway, the JAK/STAT pathway, is activated after brain injuries that lead to epilepsy, and that inhibiting this activation reduces subsequent seizure frequency in an experimental model. “We expect to identify lead JAK/STAT inhibitors that can be advanced towards clinical testing to prevent or inhibit development of acquired epilepsy following brain injury,” explained Russek.

CURE was founded by parents of children with epilepsy who were frustrated with their inability to protect their children from the devastation of seizures and the side effects of medications. Unwilling to sit back and accept the debilitating effects of epilepsy, these parents joined forces to spearhead the search for a cure. Each year, grants are funded based on promising trends in the field and the potential for breakthroughs in a specified area. Russek was selected with the assistance of the CURE Scientific Advisory Board, the Lay Review Council, and the scientific peer reviewers who generously volunteer their time to CURE.

CURE has raised more than $26 million to fund research and other initiatives. CURE funds seed grants to young and established investigators to explore new areas and collect the data necessary to apply for further funding by the National Institutes of Health. To date, CURE has awarded 151 cutting-edge projects.

Originally posted on the Boston University Medical Campus website

Maya E. Woodbury awarded PhRMA Foundation Predoctoral Fellowship

December 19th, 2013 in Student Spotlight

maya_woodbury_portrait-150x150Maya Woodbury was recently awarded the Predoctoral Fellowship in Pharmacology/Toxicology through the PhRMA Foundation. The title of her approved proposal is “miR-155/STAT3 signaling: a novel pharmacological target for Down syndrome.” For this project, she will receive financial support for her research in the amount of $20,000 per year for two years. The Foundation only awards about 10 such grants nationally each year.

According to the PhRMA Foundation’s 2012 Annual Report, “the mission of the PhRMA Foundation is to support young scientists in disciplines important to the pharmaceutical industry by awarding them competitive research fellowships and grants at a critical point at the outset of their careers. The aim is to encourage young scientists who will be the leaders of tomorrow to pursue careers in research and education related to drug discovery.”

Maya is currently a student in the Graduate Program for Neuroscience and the Biomolecular Pharmacology Program through the Department of Pharmacology & Experimental Therapeutics at Boston University School of Medicine. She works in the Laboratory of Molecular NeuroTherapeutics under the mentorship of Dr. Tsuneya Ikezu.

Congratulations, Maya!

Dr. Valentina Sabino honored by The Peter F. McManus Charitable Trust Foundation

December 18th, 2013 in Recent News

10-3009-PHARMAHEAD-086The Peter F. McManus Charitable Trust Foundation recently honored Dr. Valentina Sabino for the second time with a grant to research the causes of alcohol addiction. The title of her approved project is “Neurobiological Bases of Alcohol Addiction.”

According to Dr. Sabino, “alcoholism constitutes one of the most serious public health problems worldwide. The World Health Organization estimates that about 2 billion people worldwide consume alcoholic beverages, of which 76.3 million have alcohol use disorders. Alcohol is estimated to cause 20%–30% of esophageal cancer, liver cancer and cirrhosis, homicide, seizures, and motor vehicle accidents, causing 3.2% of the total deaths.

This project will systematically explore the role of an understudied receptor system, the Sigma receptors, in genetic and chronic ethanol-induced animal models of alcoholism. The focus will be the Nucleus Accumbens, an important brain region for alcohol and drug addiction, proposed as being the specific region where Sigma receptors mediated neuroplasticity in addicted brains.

These experiments will provide insights into this novel receptor system as a key mechanism involved in excessive drinking and alcohol-seeking behavior and propose a novel therapeutic target for alcohol addiction.”

Dr. Sabino received her Ph.D. in Pharmacology in 2006. She is an Assistant Professor in the Department of Pharmacology & Experimental Therapeutics and Department of Psychiatry, and Co-Director of the Laboratory of Addictive Disorders at Boston University School of Medicine.

Congratulations, Dr. Sabino!

Dr. Camron Bryant selected as the recipient of the 2014 IBANGS Young Scientist Award

December 18th, 2013 in Recent News

2012-11-08 13.08.21Dr. Camron Bryant has been selected as the recipient of the 2014 IBANGS Young Scientist Award. The Young Scientist Award honors a scientist who is 7 or fewer years post first faculty or faculty-equivalent appointment, and whose area of research is in behavioural and neural genetics. Key considerations are the scientific importance of research discoveries, record of achievement and future scientific plans and projected impact on the field.

Dr. Bryant, Assistant Professor of Pharmacology and Psychiatry, is the Director of the Laboratory of Addiction Genetics.

Congratulations, Dr. Bryant!

Dr. Benjamin Wolozin Receives Alzheimer’s Association Zenith Fellows Award

December 4th, 2013 in Recent News

wolozin_2006From the Office of the Dean:

I am pleased to share that Benjamin Wolozin, MD, PhD, Professor, Pharmacology and Neurology, was awarded the Alzheimer’s Association Zenith Fellows Award.  Initiated in 1991, the award provides support for cutting edge basic science or biomedical research that addresses fundamental problems related to early detection, etiology pathogenesis, treatment and/or prevention of Alzheimer’s disease (AD). The award is valued at $450,000, which will be dispersed over three years.

The Wolozin Lab won the award with its proposal “It Takes TIA to Tangle: The Role of RNA Binding Proteins in AD.” The laboratory already has discovered a RNA binding protein that induces tau misfolding, one of the essential steps that leads to cognitive loss in AD. This award will allow the Wolozin Lab to experimentally induce the misfolding, investigate the factors that regulate the misfolding and in the future, potentially design therapeutics to prevent the misfolding.

Please join me in congratulating Dr. Wolozin on this award.

Karen Antman, MD
Provost, Boston University Medical Campus
Dean, School of Medicine
Professor of Medicine

BU Pharmacology Trainee Discovers FDA Approved Treatment for MS

November 14th, 2013 in Alumni Spotlight, Recent News

RhodesKenneth J. Rhodes, Ph.D., Vice President of Neurology Discovery at Biogen Idec and an alumni of the Boston University Pharmacology Training Program, led the team of researchers that developed Tecfidera, an oral medication that defends against relapsing Multiple Sclerosis (MS).

The Food and Drug Administration recently approved Tecfidera, also known as dimethyl fumarate, for treating relapsing multiple sclerosis. This new drug delays progression of physical disability and slows the development of brain lesions associated with MS. It also reduces the inflammation caused when the immune system attacks myelin, which ultimately results in less damage to myelin in the body. In a Biogen Idec press release, Dr. Kenneth Rhodes stated that, “these exciting results support further research, as the data suggest that neublastin may have the potential to promote sensory neuronal regeneration and functional recovery following injury. The neublastin program is part of Biogen Idec’s commitment to innovative neurological science and discovery.”

According to the Boston Business Journal, Tecfidera “tops the list of the biggest potential revenue-generating drugs launched so far this year in the U.S., with expected sales of $2.9 billion by 2018.”

Dr. Kenneth Rhodes joined Biogen Idec in May 2007 after spending ten years in the Neuroscience Department at Wyeth, where he also led neurodegeneration drug discovery teams researching MS among epilepsy, stroke, Parkinson’s and Alzheimer’s disease. He served as a postdoctoral trainee under the mentorship of Dr. David H. Farb, Professor and Chair of Pharmacology at Boston University School of Medicine, from 1992-1993. Dr. Rhodes has published over 50 research papers in peer-reviewed journals such as Nature, Neuron, and the Journal of Neuroscience and most recently was the Keynote Speaker for the 2013 BU-Pfizer Symposium on “Therapeutic Innovation: Oxidative Stress and the Next Generation of Discovery” held November 5, 2013.

2013 Pfizer Symposium – “Therapeutic Innovation: Oxidative Stress and the Next Generation of Discovery

November 14th, 2013 in Event Highlights

Please click here for the 2013 BU-Pfizer Symposium program book PDF file.

Therapeutic_Innovation_Symposium_2013_poster1

Boston University Department of Pharmacology & Experimental Therapeutics – Pfizer Symposium

Tuesday, November 5, 2013   8am to 7pm
Boston University Trustee Ballroom, 1 Silber Way, 9th Floor, Boston, MA

For more information, please contact Ms. Sara Johnson at pharm3@bu.edu or 617-638-4302.

Kendra Kobrin receives Carl E. Rosow Award for Pharmacology Education

September 25th, 2013 in Student Spotlight

IMG_0219Kendra Kobrin, M.D., Ph.D. candidate in Pharmacology, received the Carl E. Rosow Award for Pharmacology Education at the Department of Pharmacology & Experimental Therapeutics New Faculty & New Student Reception held on 19 September.

Kendra graduated Summa Cum Laude from Boston University in 2008 with Bachelor degrees in both Psychology and Music. Following graduation, she spent a year as a Research Assistant in the Dermatology Department at Roger Williams Medical Center before enrolling at Boston University School of Medicine. As a second year student in the Disease and Therapy course, Kendra especially excelled in the Neurology and Psychology Modules and joined the Department of Pharmacology & Experimental Therapeutics for her dissertation work shortly thereafter. In 2011 Kendra joined Dr. Gary Kaplan’s laboratory at the VA Hospital in Jamaica Plain, where her research focuses on neuronal morphological changes associated with extinction of opioid use and relapse to drug-seeking behavior in animal models.

Kendra has excelled in both her medical and graduate pharmacology courses, serves as Tutor Coordinator for the Disease and Therapy course, and contributes to Pharmacology orientation and recruitment events. As the 2013 recipient of the Carl E. Rosow Award for Pharmacology Education, Kendra exemplifies the leadership and academic qualities we seek to foster in all of our graduate students. We are proud of Kendra’s accomplishments and enthusiastic about her bright future in research and medicine.

Dr. Carl Rosow, for whom the award is named, is an M.D., Ph.D. graduate of Boston University School of Medicine and Professor of Anesthesiology at Harvard Medical School. Since 1985 Dr. Rosow has honored his Ph.D. mentor Dr. Joseph Cochin, an internationally recognized authority on opioids, by teaching this subject to medical students in the second-year curriculum and donating his honorarium to the school. The Carl E. Rosow Award for Pharmacology Education serves both to honor graduate students for their excellence in teaching pharmacology and Dr. Rosow for his continued service to his alma mater and its students.

Congratulations to both Dr. Rosow and Kendra Kobrin for the recognition of their unwavering dedication to superior medical education.

September 2013 issue of The Pharmacologist now available

September 20th, 2013 in Recent News

TP September 2013.inddThe September 2013 issue of The Pharmacologist is now available online. Read about new Executive Officer Judith A. Siuciak, some thoughts from President Rick Neubig, the program for the Joint ASPET/Chinese Pharmacological Society Annual Meeting at Experimental Biology 2014, and more. Be sure to check it out!

 

 

 

In this issue: 

  • Introduction to new ASPET President, Judith A. Siuciak, Ph.D.
  • Message from new ASPET President, Richard R. Neubig, M.D., Ph.D.
  • ASPET Annual Meeting at Experimental Biology 2014: Program and Information
  • ASPET 2013 Annual Membership Survey Results
  • New ASPET Committee & Division Lists
  • The Case of Elizabeth Hughes: Juvenile Diabetes at the Dawn of Insulin, by Rebecca J. Anderson, Ph.D.
  • Career Center
  • Book Review, by Christine K. Carrico, Ph.D.
  • In the Spotlight: Interviews with ASPET Members
  • Obituaries: Toshio Narahashi and William L. Woolverton
  • Mid-Atlantic Pharmacology Society Annual Meeting program information
  • Great Lakes Chapter Annual Meeting abstracts

 

Originally published by the American Society for Pharmacology and Experimental Therapeutics